Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

vera therapeutics inc - VERA

VERA

Close Chg Chg %
35.28 -1.01 -2.86%

Open Market

34.27

-1.01 (2.86%)

Volume: 514.86K

Last Updated:

Sep 9, 2026, 2:40 PM EDT

Trade Now

Company Overview: vera therapeutics inc - VERA

VERA Key Data

Open

$34.84

 Day Range

34.24 - 35.48

52 Week Range

22.72 - 56.04

 Market Cap

$2.59B

Shares Outstanding

72.06M

 Public Float

58.46M

Beta

0.95

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$5.87

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.99M

  

VERA Performance

1 Week
 
 -1.70%
 
1 Month
 
 7.27%
 
3 Months
 
 2.98%
 
1 Year
 
 48.42%
 
5 Years
 
 35.02%
 

VERA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About vera therapeutics inc - VERA

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

VERA At a Glance

Vera Therapeutics, Inc.
2000 Sierra Point Parkway
Brisbane, California 94005
Phone 1-650-770-0077 Revenue 0.00
Industry Biotechnology Net Income -299,615,000.00
Sector Health Technology Employees 249
Fiscal Year-end 12 / 2026
View SEC Filings

VERA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 5.97
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -8.303
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.03

VERA Efficiency

Revenue/Employee N/A
Income Per Employee -1,203,273.092
Receivables Turnover N/A
Total Asset Turnover N/A

VERA Liquidity

Current Ratio 13.541
Quick Ratio 13.541
Cash Ratio 13.368

VERA Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -43.055
Return on Equity -50.71
Return on Total Capital -43.943
Return on Invested Capital -45.687

VERA Capital Structure

Total Debt to Total Equity 12.788
Total Debt to Total Capital 11.338
Total Debt to Total Assets 10.513
Long-Term Debt to Equity 12.697
Long-Term Debt to Total Capital 11.258
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Vera Therapeutics Inc - VERA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
(846.00K) (1.86M) 2.17M 468.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
(846.00K) (1.86M) 2.17M 468.00K
Depreciation
- - 2.17M 468.00K
-
Amortization of Intangibles
- - - -
-
COGS Growth
-580.68% -120.09% +216.49% -78.42%
Gross Income
846.00K 1.86M (2.17M) (468.00K)
Gross Income Growth
+580.68% +120.09% -216.49% +78.42%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
91.75M 103.87M 165.00M 315.00M
Research & Development
69.84M 82.31M 126.07M 214.79M
Other SG&A
21.91M 21.56M 38.93M 100.22M
SGA Growth
+169.21% +13.22% +58.85% +90.91%
Other Operating Expense
- - - -
-
Unusual Expense
- - 809.00K 47.00K
-
EBIT after Unusual Expense
(91.71M) (102.06M) (167.17M) (315.47M)
Non Operating Income/Expense
3.65M 9.86M 22.65M 23.39M
Non-Operating Interest Income
1.75M 7.98M 20.71M 24.48M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
992.00K 3.79M 7.63M 7.53M
Interest Expense Growth
+4,860.00% +281.65% +101.43% -1.25%
Gross Interest Expense
992.00K 3.79M 7.63M 7.53M
Interest Capitalized
- - - -
-
Pretax Income
(89.06M) (95.99M) (152.15M) (299.61M)
Pretax Income Growth
-173.11% -7.79% -58.50% -96.92%
Pretax Margin
- - - -
-
Income Tax
1.00K 1.00K 1.00K 1.00K
Income Tax - Current - Domestic
1.00K 1.00K 1.00K 1.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(89.06M) (95.99M) (152.15M) (299.62M)
Minority Interest Expense
- - - -
-
Net Income
(89.06M) (95.99M) (152.15M) (299.62M)
Net Income Growth
-173.10% -7.79% -58.50% -96.92%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(89.06M) (95.99M) (152.15M) (299.62M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(89.06M) (95.99M) (152.15M) (299.62M)
EPS (Basic)
-3.3517 -2.2476 -2.75 -4.6644
EPS (Basic) Growth
-118.69% +32.94% -22.35% -69.61%
Basic Shares Outstanding
26.57M 42.71M 55.33M 64.23M
EPS (Diluted)
-3.3517 -2.2476 -2.75 -4.6644
EPS (Diluted) Growth
-118.69% +32.94% -22.35% -69.61%
Diluted Shares Outstanding
26.57M 42.71M 55.33M 64.23M
EBITDA
(91.75M) (103.87M) (165.00M) (315.00M)
EBITDA Growth
-169.21% -13.22% -58.85% -90.91%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 77.143
Number of Ratings 14 Current Quarters Estimate -1.613
FY Report Date 09 / 2026 Current Year's Estimate -6.258
Last Quarter’s Earnings -1.52 Median PE on CY Estimate N/A
Year Ago Earnings -4.66 Next Fiscal Year Estimate -4.431
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 12 12
Mean Estimate -1.61 -1.47 -6.26 -4.43
High Estimates -1.39 -1.17 -5.77 -2.23
Low Estimate -1.83 -2.01 -7.11 -6.72
Coefficient of Variance -9.47 -16.69 -6.10 -23.09

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 13
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Vera Therapeutics Inc - VERA

Date Name Shares Transaction Value
Apr 16, 2026 Marshall W. Fordyce PRESIDENT AND CEO; Director 244,065 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $43.66 per share 10,655,877.90
Apr 16, 2026 Marshall W. Fordyce PRESIDENT AND CEO; Director 236,144 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.58 per share 10,527,299.52
Apr 16, 2026 Marshall W. Fordyce PRESIDENT AND CEO; Director 235,244 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45.51 per share 10,705,954.44
Dec 5, 2025 William D. Turner Chief Regulatory Officer 32,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $15.53 per share 504,725.00
Dec 5, 2025 William D. Turner Chief Regulatory Officer 22,500 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $40 per share 900,000.00
Dec 5, 2025 William D. Turner Chief Regulatory Officer 265,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2025 Jason S. Carter Chief Legal Officer 49,136 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.82 per share 1,366,963.52

Vera Therapeutics Inc in the News